Prescription drug prices frequently are at the center of public debate, and increasingly this dialogue includes discussion of gross vs net prices as well as rebates. Rarely can the question of “How much does it cost?” be answered without clarification of how price is determined. In this exclusive webinar by SSR Health LLC, the leader in US prescription drug pricing data and analytics, attendees will gain an understanding of the mid-year trends in 2019 United States (US) prescription drug pricing, marketplace pricing drivers, and pricing approaches by company, therapeutic area, and product.
Insights from the webinar will be derived from analysis of the SSR Health net price database, a well-respected source of industry data used by brand manufacturers, the Institute for Clinical and Economic Review (ICER), trade associations, policymakers, academics and the mainstream media. The proprietary dataset includes quarterly gross and net prices for approximately 1,000 US brand name prescription drugs across more than 100 companies, since 2007.
Topics addressed in the webinar include:
- Prescription drug pricing trends
- List price trajectory and impact of political pressure
- Drivers behind net price trend (formulary exclusions, co-pay accumulator effects)
- Companies, therapeutic areas and products making the largest contributions to net price trend (positive and negative)
- Political and regulatory developments related to drug pricing, including the Prescription Drug Pricing Reduction Act (PDPRA)
|The webinar will feature Dr. Richard Evans, founder and general manager of SSR Health LLC. Previously, Richard held product pricing and distribution responsibilities as a senior executive at Roche and was a top-ranked pharmaceuticals analyst at Sanford C. Bernstein. He is a is frequent commentator on drug pricing and pharmaceutical industry trends. Richard has a DVM from NC State and a MPPM from Yale University; he is the author of the book, Health and Capital, an analysis of the US healthcare system.|